Comparative effectiveness of tildrakizumab 200 mg versus tildrakizumab 100 mg in psoriatic patients with high disease burden or above 90 kg of body weight: a 16-week multicenter retrospective study – IL PSO (Italian landscape psoriasis)
Luigi GargiuloLuciano IbbaRuggero Cascio IngurgioPiergiorgio MalagoliFabrizio AmorusoAnna BalatoFederico BardazziPina BriantiGiovanna BrunassoMartina BurlandoAnna E. CagniMarzia CaproniCarlo G. CarreraAndrea CarugnoFrancesco CaudulloAldo CucciaPaolo DapavoEugenia V. Di BrizziValentina DiniFrancesca M. GaianiPaolo GisondiClaudio GuarneriClaudia LasagniGaetano LicataFrancesco LoconsoleAngelo V. MarzanoMatteo MegnaSanto R. MercuriMaria L. MusumeciDiego OrsiniSimone RiberoValentina Ruffo Di CalabriaFrancesca SatolliDavide StrippoliMassimo TravagliniEmanuele TrovatoMarina VenturiniLeonardo ZichichiMario ValentiAntonio CostanzoAlessandra Narcisia Dermatology Unit,IRCCS Humanitas Research Hospital,Rozzano,Italyb Department of Biomedical Sciences,Humanitas University,Pieve Emanuele,Italyc Department of Dermatology,Dermatology Unit Azienda Ospedaliera San Donato Milanese,Milan,Italyd Dermatology Unit,Azienda Ospedaliera di Cosenza,Cosenza,Italye Dermatology Unit,University of Campania L. Vanvitelli,Naples,Italyf Dermatology Unit,IRCCS Azienda Ospedaliero-Universitaria di Bologna,Bologna,Italyg Dermatology and Cosmetology Unit,IRCCS San Raffaele Hospital,Milan,Italyh Dermatology Department,Galliera Hospital,Genoa,Italyi Department of Dermatology,Dipartimento di Scienze della Salute (DISSAL),University of Genoa,IRCCS Ospedale Policlinico San Martino,Genoa,Italyj Unità Operativa Dipartimentale di Dermatologia e Venereologia,IRCCS San Gerardo,Milan,Italyk Immunopathology and Rare Skin Diseases Unit,Section of Dermatology,Department of Health Sciences,Azienda Unità Sanitaria Locale Toscana Centro,University of Florence,Florence,Italyl Dermatology Unit,Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico,Milan,Italym Dermatology Unit,ASST Papa Giovanni XXIII Hospital,Bergamo,Italyn PhD Program in Molecular and Translational Medicine (DIMET),University of Milan-Bicocca,Milan,Italyo Dermatology Clinic,University of Catania,Catania,Italyp Unit of Dermatology,San Donato Hospital,Arezzo,Italyq Department of Biomedical Science and Human Oncology,Second Dermatologic Clinic,University of Turin,Turin,Italyr Department of Dermatology,University of Pisa,Pisa,Italys University of Verona,Verona,Italyt Department of Biomedical and Dental Sciences and Morphofunctional Imaging,University of Messina,Messina,Italyu Dermatological Clinic,Department of Specialized Medicine,University of Modena,Modena,Italyv U.O.C. Dermatology Unit,"S. Antonio Abate" Hospital,Trapani,Italyw Department of Dermatology,University of Bari,Bari,Italyx Department of Pathophysiology and Transplantation,Università degli Studi di Milano,Milan,Italyy Section of Dermatology,Department of Clinical Medicine and Surgery,University of Naples Federico II,Naples,Italyz UOC Clinical Dermatology,Dermatological Institute S. Gallicano,IRCCS,Rome,Italyaa Unit of Dermatology,University of Parma,Parma,Italyab Dermatology Unit,ASST Lecco,Alessandro Manzoni Hospital,Lecco,Italyac U.O.S.D. dermatologica – centro per la cura della psoriasi,Ospedale Perrino,Brindisi,Italyad Unit of Dermatology,Department of Medical,Surgical and Neurological Sciences,University of Siena,Siena,Italyae Dermatology Department,University of Brescia,ASST Spedali Civili of Brescia,Brescia,Italy
DOI: https://doi.org/10.1080/09546634.2024.2350760
2024-05-08
Journal of Dermatological Treatment
Abstract:Purpose Tildrakizumab is a selective inhibitor of IL-23 approved for the treatment of moderate-to-severe plaque psoriasis in two dosages. We conducted a 16-week multicenter retrospective study to compare the effectiveness and safety of tildrakizumab 200 mg versus tildrakizumab 100 mg in patients with a high disease burden or high body weight.
dermatology